Papers
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
BMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7010.899 (Published 07 October 1995) Cite this as: BMJ 1995;311:899
Related articles
- Research Published: 22 April 2013; BMJ 346 doi:10.1136/bmj.f1798
Cited by...
- Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
- Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis
- Consolidation treatments after chemoradiotherapy in patients with locally advanced inoperable non-small cell lung cancer: a systematic review and network meta-analysis protocol
- Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells
- Feasibility and safety of shortened hypofractionated high dose palliative lung radiotherapy - A retrospective planning study
- Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience
- Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities
- Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation
- Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer
- Feasibility of Concomitant Chemoradiotherapy in Daily Practice for Patients with NSCLC Stage III
- Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?
- Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome
- Demethoxycurcumin-induced DNA Damage Decreases DNA Repair-associated Protein Expression Levels in NCI-H460 Human Lung Cancer Cells
- Optimal First-Line and Maintenance Treatments for Advanced-Stage Nonsquamous Non-Small Cell Lung Cancer
- Recent Clinical Advances in Lung Cancer Management
- Advances in the Diagnosis and Treatment of Non-Small Cell Lung Cancer
- Split-dose Cisplatin and Vinorelbine as Adjuvant Chemotherapy for Completely Resected Non-small Cell Lung Cancer
- Pemetrexed and Cisplatin for Advanced Non-squamous Non-small Cell Lung Cancer in Japanese Patients: Phase II Study
- Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews
- Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial
- Therapeutic advances in non-small cell lung cancer
- Utility of Hypertension as a Surrogate Marker for Efficacy of Antiangiogenic Therapy in NSCLC
- Preoperative Chemoradiotherapy Using Cisplatin plus S-1 Can Induce Downstaging in Patients with Locally Advanced (Stage III) Non-Small-Cell Lung Cancer
- Survival Following Surgery with or without Adjuvant Chemotherapy for Stage I-IIIA Non-Small Cell Lung Cancer: An East Asian Population-Based Study
- Non-Small Cell Lung Cancer
- First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial
- Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis
- The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer
- Selection of chemotherapy for patients with advanced non-small cell lung cancer
- The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy
- RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
- Senior Adult Oncology
- Impacts of Treatment Lines and Initiation Timing of Erlotinib for Advanced Non-small Cell Lung Cancer
- Treatment of Non-Small Cell Lung Cancer in the Older Patient
- Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations
- Vinorelbine versus Paclitaxel for Patients with Advanced Non-small Cell Lung Cancer (NSCLC) and a Performance Status of 2
- Genetic Variation Predicting Cisplatin Cytotoxicity Associated with Overall Survival in Lung Cancer Patients Receiving Platinum-Based Chemotherapy
- Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors
- FDG-PET as a Potential Tool for Selecting Patients with Advanced Non-Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer
- Effect of Amifostine on Survival Among Patients Treated With Radiotherapy: A Meta-Analysis of Individual Patient Data
- Role of Postoperative Radiotherapy in Resected Non-Small Cell Lung Cancer: A Reassessment Based on New Data
- A Retrospective Analysis of Non-platinum-based First- and Second-line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
- Guidelines on the radical management of patients with lung cancer
- The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
- Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions
- Non-Small Cell Lung Cancer
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
- Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non-Small Cell Lung Cancer
- Liposomal Cisplatin Dose Escalation for Determining the Maximum Tolerated Dose and Dose-limiting Toxicity: A Phase I Study
- Adverse Events Among the Elderly Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer
- Histology Matters: Individualizing Treatment in Non-Small Cell Lung Cancer
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer
- Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: It Does Not Always Fade With Time
- Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma
- Duration of Chemotherapy for Metastatic Non-Small-Cell Lung Cancer: More May Be Not Better
- Prognostic significance of hypoxia-inducible factor-1{alpha}, TWIST1 and Snail expression in resectable non-small cell lung cancer
- Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin
- Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
- Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial
- Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer
- Duration of Chemotherapy for Metastatic Non-Small-Cell Lung Cancer: More May Be Better After All
- Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
- Re-Evaluating Duration of Therapy in Advanced Non-Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?
- ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
- Randomized Phase II Study of Gefitinib Compared With Placebo in Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status
- Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
- Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer
- Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer
- First- and second-line therapy for advanced nonsmall cell lung cancer
- Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
- Prognostic gene signatures for non-small-cell lung cancer
- Polymerase {eta} mRNA Expression Predicts Survival of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
- Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect?
- Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
- Quality-of-Life Outcomes for Adjuvant Chemotherapy in Early-Stage Non-Small-Cell Lung Cancer: Results From a Randomized Trial, JBR.10
- Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials
- Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non-Small-Cell Lung Cancer
- Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505
- Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- Modern Radiotherapy as Part of Combined Modality Treatment in Locally Advanced Non-Small Cell Lung Cancer: Present Status and Future Prospects
- ECSA/DPPA2 is an Embryo-Cancer Antigen that Is Coexpressed with Cancer-Testis Antigens in Non-Small Cell Lung Cancer
- Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
- Carcinoma of the bronchus 60 years later
- Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non-Small-Cell Lung Cancer
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
- Adjuvant Chemotherapy for Lung Cancer: Cisplatin Doublets Only?
- Neoadjuvant Chemotherapy in Stage III NSCLC
- Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non-Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials
- Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
- Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline
- Chemotherapy improves low performance status lung cancer patients
- Duration of First-Line Chemotherapy in Advanced Non Small-Cell Lung Cancer: Less Is More in the Era of Effective Subsequent Therapies
- Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non Small-Cell Lung Cancer
- Phase II Clinical Trial of the Epothilone B Analog, Ixabepilone, in Patients With Non Small-Cell Lung Cancer Whose Tumors Have Failed First-Line Platinum-Based Chemotherapy